Pole Hospitalier Jolimont

La Louviere 14 trials 6 recruiting

14 Registered trials

6 Currently recruiting

Organisation

Pole Hospitalier Jolimont

Location

La Louviere, Belgium

Identifier

ORG-100041875

Address

Rue Ferrer 159, 7100, Belgium

Departments

Department of Hematology
Gastroenterology
Hemato-Oncology and Radiotherapy Unit
Hematology
Infectious Diseases
Intensive Care Unit
Medical Oncology
N/A
Oncology
Radiology

Clinical trials at this site (14)

Search interface

Baricitinib for treating hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase II … Not authorised

2023-503480-42-00 Hospital-acquired pneumonia 10
A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che… Recruiting

2022-502660-20-00 Follicular lymphoma 5 2024-01-23
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagn… Recruiting

2022-501709-11-00 Isocitrate deshydrogenase1 mutation-positive (IDH1m) ac 5 2023-06-06
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline … Recruiting

2022-501181-22-01 Pancreatic adenocarcinoma 4 2023-02-06
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable LA HNSCC (Locoregionally Advanced Head and Neck Squamo… Ended

2022-500254-41-00 Stage III-IVA Resectable Locoregionally Advanced Head a 5 2018-12-13
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Ended

2023-505246-26-00 High- or very-high risk, localized or locally advanced 5 2016-01-27
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended

2022-500177-13-00 Metastatic Colorectal Cancer (mCRC) 4 2023-06-02
Cohort study of human mpox virus disease Ended

2022-501132-42-00 Monkeypox virus disease 6 2022-08-02